Large Cohort of 1000 Patients With Severe Myopia
ConditionMyopia, Severe
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age6+
SponsorCentre Hospitalier National d'Ophtalmologie des Quinze-Vingts
About this trial
The prevalence of myopia and severe myopia are increasing and will affect 50% and 10% of the population respectively. Severe myopia exposes an increased risk of glaucoma, cataract, retinal detachment and myopic maculopathy, a source of visual impairment.
To date, no European cohort study has been conducted to estimate the rate of these complications and to study the predictive parameters.
Eligibility criteria
Qualifiers
Age ≥ 6 years
Severe myopia in at least one eye, defined as
a refractive error ≤ -6.00 diopters OR
an axial length ≥ 26.50 mm
Disqualifiers
Visual acuity < 5 letters on the ETDRS (equivalent to "finger count" or less) in both eyes
Disorders of the transparent media in both eyes with opacities that may affect image quality
Syndromic myopia of genetic origin (Stickler syndrome type 1 and 2, Marfan syndrome, Ehler-Danlos disease type 4, Knobloch syndrome) or inherited retinal dystrophy (X-linked retinitis pigmentosa, congenital stationary night blindness of Schubert-Bornshein type, Bornholm eye disease)
Patient who does not wish to continue to be followed in one of the participating centers
Trial design
Treatments tested in this trial
- Structural and fonctional phynotyping
Treatment groups
1,000 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
Lead sponsor
Fondation Ophtalmologique Adolphe de Rothschild
Collaborator
Source ClinicalTrials.gov